Interview with Ulf Schneider, Managing Partner, RUSSIA CONSULTING
You founded this business in 2003, and it has since grown to encompass five offices and over 250 experts. Can you tell our readers a bit about the history behind…
Address: 23 Novoslobodskaya ulitsa
5e étage, bureau 560
127055 Moscou
Tel: +7 (495) 721 38 28
Web: http://www.ccifr.ru/
The Franco-Russian Chamber of Commerce and Industry (CCIFR) is an independent
lobbying body that represents and promotes the economic interests of its
Franco-Russian member companies.
The CCIFR has been operating in Moscow since 1997, when the Le Club France
was created. The business club developed naturally, becoming the Chamber of Commerce
and Industry in 2006 after becoming a member of the Union of French Chambers
of Commerce and Industry abroad (UCCIFE), the first private network of French
companies in the world, represented in 78 countries and incorporating over 25,000
companies.
Led by a team of permanent professionals under the authority of 18 volunteer
administrators, the CCIFR is a nonprofit association financed mainly by contributions
from its 300 members. Receiving no public subsidies, and not being under any kind
of governmental supervision, the CCIFR is the legitimate, objective and independent
voice of the Franco-Russian business community.
Its work is concentrated in 3 main areas of activity:
• Building the business community: organization and staging of sectoral committees
(Customs/Logistics/Certification, Tax & Accounting, Marketing &
PR, HR), business presentations and B2B meetings, cultural events, and delegations
from regional companies.
• Lobbying: consultations and dialogues with French and Russian private and public
policy makers, with support of its numerous partners (business communities, governments,
politicians and regional organizations). The CCIFR has signed cooperation
agreements with more than fifteen governments and Chambers of Commerce and
Industry in various Russian regions.
• Support for companies: support for establishing and developing French businesses
in Russia, and Russian investment in France.
You founded this business in 2003, and it has since grown to encompass five offices and over 250 experts. Can you tell our readers a bit about the history behind…
The following is an interview with Dr. Smirnov, as well as Dr. Dmitri Pavlovich, Director, Clinical Operations Russia Quintiles very recently announced the launch of its first commercial project in…
The following is an interview with Dr. Pavlovich, as well as Dr. Sergey Smirnov, Director, Business Development and Operations, CEE, CIS and Russia Quintiles very recently announced the launch of…
You have lead this company since its beginnings in 2003, when it acquired ICN pharmaceuticals. In 2007, Pharmstandard carried out an IPO of 43% of its shares. How has the…
You were working for GSK since 2003 before joining Galderma this year. Some within the industry might view Galderma as a step down from the third-ranked pharmaceutical company in the…
GSK CEO Andrew Witty has said that GSK must move away from selling “white pills in Western markets” in order to offset widespread generic erosion. This means diversifying the company’s…
The following is joint interview of Mr. Vayntrub and Regina Karymova, General Manager of Invar Mr. Vayntrub, you founded Invar in 1991, and began to capitalize on foreign investment in…
Pepeliaev, Goltsblat & Partners and the major UK firm Berwin Leighton Paisner (BLP). It calls itself the first international Russian law firm. Can you explain to our readers the rationale…
Janssen recently signed memorandums of understanding with both the Skolkovo Foundation and ChemRar. Can you describe the strategic parameters and intended outcomes of these agreements? How do they factor into…
Mr. Demidov, you are one of the pioneers of market research studies in Russia. There is a quote you like to use: ‘Market research is a business in the United…
How would you describe CMS’s own presence in the life sciences field in Russia, and what unique competitive advantages does the firm bring to this area of practice? Over the…
With the announcement of the Pharma 2020 strategy to develop the domestic pharmaceutical industry, multinational companies have pledged an excess of $1Bn in investment into local infrastructure. Servier, however, preempted…
See our Cookie Privacy Policy Here